You are here
Articles
Posted on Friday, October 2, 2009 - 11:25am
EMEA website provides information about the role and activities of the European Medicines Agency in relation to the current H1N1 influenza ('swine flu') pandemic. It also provides information on the development and...
Posted on Friday, August 14, 2009 - 2:36pm
Poster for CML Patient and Carer Education Day
14th November 2009 at
The Crown Plaza Hotel, Nottingham, UK...
Posted on Tuesday, August 11, 2009 - 11:39am
Capsule Summary
CCO-Independent Conference Coverage of the American Society of Clinical Oncology Annual Meeting, June 2009*Omacetaxine Active With Minimal Toxicity in T315I-...
Posted on Friday, July 17, 2009 - 12:03pm
Cutting-edge drugs to be fast-tracked, bypassing NICE
15 July 2009
The UK government has announced plans to allow highly innovative drugs to be made available on the NHS for a limited period without going through...
Posted on Monday, June 29, 2009 - 1:53pm
At 24th of June 2009 a new campaign European Action Against Rare Cancers has been launched. The new campaign urges European policy-makers to prioritise better treatment and care for patients with rare cancers within the...
Posted on Thursday, June 18, 2009 - 12:23pm
May 22 (HealthDay News) -- Low levels of vitamin D may contribute to cancer development, U.S. researchers have found.
Posted on Friday, June 12, 2009 - 11:23am
Interim guidance for use of 23-valent pneumococcal polysaccharide vaccine during novel influenza A (H1N1) outbreak
June 9, 2009
Table. U.S. ACIP recommendations for use of pneumococcal polysaccacharide vaccine.
Posted on Tuesday, June 9, 2009 - 12:07pm
Persistent CML-initiating cells, or CML stem cells, which are protected from imatinib killing by their quiescent status, are
probably responsible for the regrowth of the disease.
Posted on Tuesday, June 2, 2009 - 10:32am
Life Extension Magazine
June 2, 2009
New model of cancer development proposed
In an article scheduled to appear in the Annals of Epidemiology, epidemiologist Cedric Garland, DrPH and his associates at the University of...
Posted on Monday, June 1, 2009 - 12:37pm
Clinical, pharmacokinetic (PK), and pharmacodynamic findings from a phase I trial of an Eg5 inhibitor (AZD4877) in patients with refractory acute myeloid leukemia (AML).
Posted on Thursday, May 7, 2009 - 11:44am
Recognition for inventors in the fight against disease
[Date: ]
The fight against leukaemia and malaria - two of the world's most virulent diseases - was rewarded in two out of the four categories at the recent European...
Posted on Thursday, April 30, 2009 - 1:30pm
NICE opens NHS door to blood cancer therapy Revlimid
27 April 2009
It was further good news for patients with multiple myeloma in the UK last week after the National Institute for Health and Clinical Excellence cemented...
Posted on Monday, April 27, 2009 - 1:07pm
ChemGenex statement.
Posted on Monday, April 27, 2009 - 12:55pm
A trial of omacetaxine for chronic myeloid leukaemia in people who cannot take tyrosine kinase inhibitors (TKIs) or whose leukaemia has not responded to TKIs
This trial is looking at a drug called omacetaxine (OM) for...
Posted on Monday, April 6, 2009 - 10:12am
Guidance on NHS patients who wish to pay for additional private care:
Executive summary
The key points which NHS organisations should take from this guidance are:
• NHS organisations should not withdraw...
- ‹ previous
- 27 of 33
- next ›